药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Nemonoxacin
The risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Telavancin
The risk or severity of QTc prolongation can be increased when Telavancin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Tucidinostat
The risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Tedisamil
The risk or severity of QTc prolongation can be increased when Tedisamil is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Garenoxacin
The risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Technetium Tc-99m ciprofloxacin
The risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Pracinostat
The risk or severity of QTc prolongation can be increased when Pracinostat is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Azimilide
The risk or severity of QTc prolongation can be increased when Azimilide is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Fluspirilene
The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Prenylamine
The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Terlipressin
The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Terodiline
The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Terodiline.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Macimorelin
The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Macimorelin.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Ribociclib
The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Ribociclib.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Lumefantrine
The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Lumefantrine.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Artemether
The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Artemether.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Asenapine
The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Asenapine.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Avanafil
The metabolism of Avanafil can be decreased when combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Sonidegib
The metabolism of Sonidegib can be decreased when combined with Berotralstat.
6-(4-{[2-(3-iodobenzyl)-3-oxocyclohex-1-en-1-yl]amino}phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one
Naloxegol
The metabolism of Naloxegol can be decreased when combined with Berotralstat.